Claris Life Sciences on Thursday said it has received approval from Russia to market its Fluconazole and Levofloxacin injections, used for treating fungal and bacterial infections.
The approval from Russia’s Ministry of Health is to market two anti-infectives - Fluconazole IV 100-ml and Levofloxacin IV 100-ml, Claris Life Sciences said in a filing to the Bombay Stock Exchange (BSE).
While Fluconazole is indicated for treatment and prevention of superficial fungal infections, Levofloxacin is used in treating a broad range of infections, it said.
“With its knowledge of emerging markets and a competent sales force, Claris will be able to replicate the success in Russia, similar to what it has achieved in other emerging markets,” the company said.
With these two approvals, the company has now four anti-infective product approvals in Russia. “The total market size of these four parenteral products is estimated to be $53 million,” it said, adding that the company has another four products in the pipeline for registration in Russia.
Shares of Claris Life Sciences were being quoted at Rs 162.60 a piece on the BSE in late afternoon trade today, down 1.75 per cent from their previous close.